Tuesday, December 17, 2013

NEW breast cancer research presentations for the Symphony suite of breast cancer tests (MammaPrint ® & BluePrint ®)


Last week I was privileged to see the 10 NEW breast cancer research presentations for the Symphony suite of breast cancer tests (MammaPrint ® & BluePrint ®) at the 2013 San Antonio Breast Cancer Symposium in Texas.

“These ten studies further demonstrate Agendia’s continued commitment to providing the oncology community and their breast cancer patients with the most comprehensive and validated picture of tumor biology available in the market,” said Neil Barth, M.D., Agendia’s Chief Medical Officer. 
 
Symphony is the only widely available test suite providing molecular subtyping -- a recent advancement in breast cancer prognosis and treatment that is highlighted in several SABCS posters. The second-generation MammaPrint test provides definitive High Risk or Low Risk information about breast cancer recurrence, with no “intermediate” results. 

WIth this new information, I will now be able to better assist my patients with their decision making regarding which forms of treatment they now need to undergo.